The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Organon launches Herceptin biosimilar in Canada

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Organon launched the distribution of Ontruzant, a biosimilar of Herceptin, in Canada, providing an additional treatment option for Canadian adults diagnosed with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Verzenio delivers OS benefit in high-risk early breast cancer

Two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, according to the primary overall survival analysis of the phase III monarchE trial.
Clinical Roundup

Imfinzi-based regimen reduced the risk of death in early gastric cancer vs. chemotherapy alone

Perioperative treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival versus chemotherapy alone, according to MATTERHORN phase III trial results. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account